Immunotherapy plus chemo for older adults with stage 3 stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy after surgical removal of stomach cancer can prevent the cancer from returning in older adults (aged 65 and above). The study aims to see if this combination improves outcomes compared to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have had surgery to completely remove stomach cancer, with no cancer left behind, within the past 6 weeks.
- Your cancer is stage 3, based on postsurgical evaluation.
- You are in good physical health, as judged by a score of 0 or 1 on a standard activity scale.
- You have not received any previous cancer treatment (chemotherapy, radiation, or immunotherapy) for this cancer before surgery.
- Your cancer cells show a PD-L1 CPS score of 1 or higher, indicating a potential response to the study drug.
- Your blood counts, liver and kidney function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.